Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine,
ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled
trials (RCTs) for efficacy and/or safety evaluations in patients with COVID-19 in different
countries. Remdesivir (GS-5734) is among these investigational drugs and some studies
reported promising results. Remdesivir is a nucleotide analogue intravenous pro-drug
developed by Gilead Sciences, an American biopharmaceutical company, for treatment of Ebola
virus during the 2014 Ebola outbreak in Western Africa. Remdesivir shows broad-spectrum
antiviral activity against many RNA viruses including SARS-CoV-2 through blocking RNA
polymerase thereby terminating RNA transcription. Remdesivir was among the first treatments
used in China as the outbreak emerges and it has been reported as potential treatment options
for COVID-19 in the USA, China and Italy.